专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016010773A1 APPLYING MESH NETWORK TO STADIUM SERVICES 审中-公开
标题翻译：将网络应用于体育服务
公开(公告)号：WO2016010773A1
公开(公告)日：2016-01-21
申请号：PCT/US2015/039378
申请日：2015-07-07
申请人： SONY CORPORATION , MILNE, James R. , CARLSSON, Gregory Peter , ZUSTAK, Frederick J.
发明人： MILNE, James R. , CARLSSON, Gregory Peter , ZUSTAK, Frederick J.
IPC分类号： G06Q30/06 , H04M3/42
CPC分类号： H04W4/33 , G06Q30/0635 , G06Q30/0639 , H04W4/04 , H04W84/18
摘要： Mesh node modules are associated with stadium seats and companion nodes such as fan CE devices can dynamically form a mesh network which uploads information of the nodes to a network. Sporting information may be downloaded to a fan's CE device or services provided to the fan while in a seat based on information sent through the node modules in the stadium.
摘要翻译：网状节点模块与体育场座位和伴随节点（如风扇CE设备）相关联，可以动态地形成将节点的信息上传到网络的网状网络。运动信息可以根据通过体育场内的节点模块发送的信息，下载到风扇的CE设备或提供给风扇的服务。

2. 发明申请

WO2012083379A1 IMPROVEMENTS TO A METAL DETECTOR WITH INTEGRATED MEASUREMENT OF SENSOR HEAD MOTION 审中-公开
标题翻译：对传感器头部运动进行综合测量的金属探测器的改进
公开(公告)号：WO2012083379A1
公开(公告)日：2012-06-28
申请号：PCT/AU2011/001674
申请日：2011-12-22
申请人： MINELAB ELECTRONICS PTY LIMITED , HARMER, Gregory, Peter , STAMATESCU, Laurentiu , BECK, Philip, David , KURSA, Pavel Valentine
发明人： HARMER, Gregory, Peter , STAMATESCU, Laurentiu , BECK, Philip, David , KURSA, Pavel Valentine
IPC分类号： G01V3/08
CPC分类号： G01V3/10
摘要： A method for triggering one or more predetermined functions during a detection of a target in a soil, including: transmitting a transmit magnetic field; receiving a receive magnetic field using a magnetic field receiver to produce a receive signal; detecting a movement of the magnetic field receiver relative to the soil; analysing the movement to produce an analysis result; and performing, based on the analysis result, one or more of the one or more predetermined functions.
摘要翻译：一种用于在检测土壤中的目标物时触发一个或多个预定功能的方法，包括：发送发射磁场; 使用磁场接收器接收接收磁场以产生接收信号; 检测磁场接收器相对于土壤的移动; 分析运动产生分析结果; 以及基于所述分析结果执行所述一个或多个预定功能中的一个或多个。

3. 发明申请

WO2008079685A2 LIPASE VARIANTS FOR PHARMACEUTICAL USE 审中-公开
标题翻译：用于药物使用的脂肪变体
公开(公告)号：WO2008079685A2
公开(公告)日：2008-07-03
申请号：PCT/US2007/087168
申请日：2007-12-12
申请人： NOVOZYMES A/S , NOVOZYMES, INC. , SOLVAY PHARMACEUTICALS GMBH , SVENDSEN, Allan , SKJOET, Michael , YAVER, Debbie , CHRISTENSEN, Lars, Lehmann, Hylling , LARSEN, Signe, Eskildsen , LUNDIN, Nina , LAMSA, Michael , GREGORY, Peter, Colin
发明人： SVENDSEN, Allan , SKJOET, Michael , YAVER, Debbie , CHRISTENSEN, Lars, Lehmann, Hylling , LARSEN, Signe, Eskildsen , LUNDIN, Nina , LAMSA, Michael , GREGORY, Peter, Colin
IPC分类号： C12N9/20 , A61K38/46 , A61K38/54
CPC分类号： A61K38/465 , A61K38/47 , A61K38/48 , C12N9/20
摘要： The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
摘要翻译：与包含SEQ ID NO：2的氨基酸1-269的Thermomyces lanuginosus（Humicola lanuginosa）脂肪酶相关的脂肪酶的药物用途，任选地与蛋白酶和/或淀粉酶组合。医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。本发明的脂肪酶具有例如体外改进的消化性能，在中性范围内的pH值改善的活性，在低pH下的改进的稳定性，对蛋白酶降解是稳定的，和/或在存在时是稳定的的胃蛋白酶和胆汁盐。本发明还涉及确定脂肪酶的体外消化性能的方法以及T.lanuginosus的脂肪酶的某些新颖变体。

4. 发明申请

WO2007125049A1 USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS 审中-公开
标题翻译： CBX CANNABINOID受体调节剂作为钾通道调节剂的使用
公开(公告)号：WO2007125049A1
公开(公告)日：2007-11-08
申请号：PCT/EP2007/053915
申请日：2007-04-20
申请人： SOLVAY PHARMACEUTICALS GMBH , ANTEL, Jochen , GREGORY, Peter-Colin , LANGE, Josephus Hubertus Maria , FIRNGES, Michael , REICHE, Dania
发明人： ANTEL, Jochen , GREGORY, Peter-Colin , LANGE, Josephus Hubertus Maria , FIRNGES, Michael , REICHE, Dania
IPC分类号： A61K31/353 , A61K31/425 , A61K31/415 , A61K31/454 , A61K31/09 , A61K31/542 , A61K31/5415 , A61P3/04 , A61P3/10 , A61P9/06 , A61P9/10 , A61P13/10 , A61P15/10 , A61P17/14 , A61P25/28
CPC分类号： A61K31/09 , A61K31/353 , A61K31/415 , A61K31/425 , A61K31/454 , A61K31/5415 , A61K31/542
摘要： The invention is directed to the use of at least one CB x modulator wherein the CB x modulator is selected from the group consisting of CB 1 agonists; CB 2 agonists; CB 2 partial agonists; CB 2 antagonists; CB 2 inverse agonists; and dually acting compounds which are both a CB 1 agonist and a CB 2 agonist; and mixtures thereof, as K ATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CB x modulator having K ATP channel modulating properties.
摘要翻译：本发明涉及使用至少一种CB-X调节剂，其中CB调节剂选自CB 1激动剂 ; CB 2激动剂; CB 2/2部分激动剂; CB 2拮抗剂; CB 2反向激动剂; 和作为CB 1激动剂和CB 2 N 2激动剂的双作用化合物; 和其混合物，作为用于预防，治疗，延迟进展，延迟发作和/或抑制多种疾病状况（包括肥胖症，糖尿病，代谢综合征，综合征X，胰岛素瘤）的K ATP通道调节剂，家族性高胰岛素低血糖，男性型秃发，逼尿肌反应性过高，哮喘，神经保护，癫痫，镇痛，心脏保护，心绞痛，心跳停搏，心律失常，冠状动脉痉挛，外周血管疾病，脑血管痉挛，食欲调节，神经变性，疼痛 - 包括神经性疼痛和慢性疼痛和哺乳动物和人类的阳。。本发明还涉及治疗，预防，延缓发病和/或抑制各种疾病状况（包括肥胖症，糖尿病，代谢综合征，综合征X，胰岛素瘤，家族性高胰岛素低血糖，男性型秃发，逼尿肌）的进展，高反应性，哮喘，神经保护，癫痫，止痛，心脏保护，心绞痛，心脏停跳，心律失常，冠状动脉痉挛，外周血管疾病，脑血管痉挛，食欲调节，神经变性，疼痛 - 包括神经性疼痛和慢性疼痛 - 以及哺乳动物和人的阳humans 涉及有需要的受试者有效量的至少一种具有K ATP通道调节特性的CB调节剂。

5. 发明申请

WO2006136160A3 PROTEASES FOR PHARMACEUTICAL USE 审中-公开
标题翻译：用于药物使用的食品
公开(公告)号：WO2006136160A3
公开(公告)日：2007-09-20
申请号：PCT/DK2006000353
申请日：2006-06-16
申请人： NOVOZYMES AS , SOLVAY PHARM GMBH , SVENDSEN ALLAN , FUGLSANG CLAUS CRONE , GREGORY PETER COLIN
发明人： SVENDSEN ALLAN , FUGLSANG CLAUS CRONE , GREGORY PETER COLIN
IPC分类号： A61K38/48 , A61K38/54 , C12N9/54
CPC分类号： C12N9/54
摘要： The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.
摘要翻译：与SEQ ID NO：2的氨基酸1-274相关的蛋白酶的药物用途，来自地衣芽孢杆菌的丝氨酸蛋白酶，其也被指定为枯草杆菌蛋白酶卡尔斯伯格，任选与脂肪酶和/或淀粉酶组合。医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。

6. 发明申请

WO2007091224A1 CLAMSHELL PACKAGE FOR HOLDING AND DISPLAYING CONSUMER PRODUCTS 审中-公开
标题翻译：用于保存和显示消费品的CLAMSHELL包装
公开(公告)号：WO2007091224A1
公开(公告)日：2007-08-16
申请号：PCT/IB2007/050437
申请日：2007-02-09
申请人： THE PROCTER & GAMBLE COMPANY , DALEA, Gregory, Peter , WESSLING, Gary, Allen , WALTERS, Gregory, Alan , JOHNSON, Kent, David
发明人： DALEA, Gregory, Peter , WESSLING, Gary, Allen , WALTERS, Gregory, Alan , JOHNSON, Kent, David
IPC分类号： B65D75/24
CPC分类号： B65D75/245 , B65D2201/00
摘要： A clamshell package (10) is provided for holding and displaying a consumer product that comprises a bottle (17) and a cap (19) . The clamshell package comprises a first clamshell side and a second clamshell side, wherein at least a portion of the first and second clamshell sides are affixed together to hold the consumer product between the first and second clamshell sides. The clamshell package further comprises an aperture (15) through which at least a portion of the cap of the consumer product extends from the clamshell package. The clamshell package is therefore able to hold and display the consumer product, while allowing a consumer to access the cap of the product in order to smell or to sample the product. A clamshell package is further provided for holding and displaying a consumer product comprising liquid composition contained in a tottle.
摘要翻译：提供了一种蛤壳式包装（10），用于保持和显示包括瓶子（17）和帽子（19）的消费品。蛤壳式包装包括第一蛤壳侧和第二蛤壳侧，其中第一和第二蛤壳侧的至少一部分被固定在一起以将消费品保持在第一和第二蛤壳之间。蛤壳式包装还包括孔（15），消费品的帽的至少一部分从蛤壳包装延伸穿过该孔。因此，蛤壳式包装件能够容纳和显示消费品，同时允许消费者访问产品的帽子以闻起来或对产品进行取样。进一步提供一种蛤壳式包装，用于容纳和显示包含在小容器中的液体组合物的消费品。

7. 发明申请

WO2006136161A3 AMYLASES FOR PHARMACEUTICAL USE 审中-公开
标题翻译：制药用AMYLASES
公开(公告)号：WO2006136161A3
公开(公告)日：2007-07-05
申请号：PCT/DK2006000354
申请日：2006-06-16
申请人： NOVOZYMES AS , SOLVAY PHARM GMBH , SVENDSEN ALLAN , GREGORY PETER COLIN
发明人： SVENDSEN ALLAN , GREGORY PETER COLIN
IPC分类号： A61K38/47 , A61K38/54 , C12N9/28
CPC分类号： C12N9/2417
摘要： The pharmaceutical use of amylases related to Bacillus alpha-amylases of SEQ ID NOs: 1-3, optionally in combination with a lipase and/or a protease. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The amylases of SEQ ID NOs: 1-3 are variants of amylases from Bacillus stearothermophilus, Bacillus licheniformis and Bacillus sp. The amylases of the invention have an improved efficacy in vivo, an improved pH-profile, a high specific activity, and/or an improved starch degradation profile.
摘要翻译：与SEQ ID NO：1-3的芽孢杆菌α-淀粉酶相关的淀粉酶的药物用途，任选地与脂肪酶和/或蛋白酶组合。医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。 SEQ ID NO：1-3的淀粉酶是来自嗜热脂肪芽孢杆菌，地衣芽孢杆菌和芽孢杆菌属的淀粉酶的变体。本发明的淀粉酶在体内具有改善的功效，改善的pH分布，高比活性和/或改进的淀粉降解特征。

8. 发明申请

WO2007065948A1 NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS 审中-公开
标题翻译：用于预防或治疗肥胖及相关情况的新型N-磺酰胺哌啶胺
公开(公告)号：WO2007065948A1
公开(公告)日：2007-06-14
申请号：PCT/EP2006/069482
申请日：2006-12-08
申请人： SOLVAY PHARMACEUTICALS GMBH , ANTEL, Jochen , SCHOEN, Uwe , WALDECK, Harald , WURL, Michael , FIRNGES, Michael , REICHE, Dania , GREGORY, Peter-Colin
发明人： ANTEL, Jochen , SCHOEN, Uwe , WALDECK, Harald , WURL, Michael , FIRNGES, Michael , REICHE, Dania , GREGORY, Peter-Colin
IPC分类号： C07D211/58 , C07D401/04 , C07D409/12 , C07D401/12 , A61K31/4545 , A61P3/04
CPC分类号： C07D409/12 , C07D211/58 , C07D401/04 , C07D401/12
摘要： The present invention relates to novel N-sulfamoyl-piperidineamides of general formula (I) and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and/or related conditions.
摘要翻译：本发明涉及通式（I）的新型N-氨磺酰 - 哌啶酰胺及其生理上可接受的酸加成盐，涉及包含它们的药物组合物，其制备方法及其用于治疗肥胖及其伴随和/或继发性疾病和/或相关病症。

9. 发明申请

WO2006136159A3 LIPASES FOR PHARMACEUTICAL USE 审中-公开
标题翻译：用于药物使用的药物
公开(公告)号：WO2006136159A3
公开(公告)日：2007-04-12
申请号：PCT/DK2006000352
申请日：2006-06-16
申请人： NOVOZYMES AS , SOLVAY PHARM GMBH , SVENDSEN ALLAN , BORCH KIM , GREGORY PETER COLIN
发明人： SVENDSEN ALLAN , BORCH KIM , GREGORY PETER COLIN
IPC分类号： C12N9/20 , A61K38/46 , A61K38/54
CPC分类号： C12N9/20
摘要： The pharmaceutical use of lipases related to a variant of the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 1, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have an improved efficacy in vivo, are stable against protease-degradation, and/or are stable in the presence of bile salts.
摘要翻译：与包含SEQ ID NO：1的氨基酸1-269的Thermomyces lanuginosus（Humicola lanuginosa）脂肪酶的变体相关的脂肪酶的药物用途，任选地与蛋白酶和/或淀粉酶组合。医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。本发明的脂肪酶在体内具有改善的功效，对蛋白酶降解是稳定的，和/或在胆汁盐存在下是稳定的。

10. 发明申请

WO2006045799A3 PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS 审中-公开
公开(公告)号：WO2006045799A3
公开(公告)日：2006-05-04
申请号：PCT/EP2005/055534
申请日：2005-10-25
申请人： SOLVAY PHARMACEUTICALS GMBH , FIRNGES, Michael , GREGORY, Peter-Colin , ANTEL, Jochen , LANGE, Josephus Hubertus Maria , WALDECK, Harald
发明人： FIRNGES, Michael , GREGORY, Peter-Colin , ANTEL, Jochen , LANGE, Josephus Hubertus Maria , WALDECK, Harald
IPC分类号： A61K31/00 , A61K31/54 , A61K31/40 , A61K31/44 , A61K31/415 , A61K31/427 , C12Q1/68 , A61P3/04 , G01N33/00
摘要： Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one K ATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB 1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising K ATP channel openers and CB1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type I, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhibition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined K ATP channel opening and CB 1 antagonistic properties.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式